Идёт набор NCT06278285

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Без фазы С лечением Obesity

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Blood GLP1, Blood No treated GLP1.
Кому может быть актуально: Состояния в реестре: Obesity. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Франция
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Вмешательства

Другое Blood GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
Другое Blood No treated GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.

Первичные конечные точки

Rate of oxytocin [Срок оценки: one time (before surgery)]

Вторичные конечные точки (1)

Fibrosis rate [Срок оценки: At surgery]

Критерии участия

Критерии включения

Patient over 18 years of age.
Patient able to read and understand the information/consent leaflet.
Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
Membership of a social security scheme
Patient's signed informed consent
For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
For non-GLP-1 analogue group: never taken GLP-1 analogues.